Vascular Patches Market (2026 - 2033)

Vascular Patches Market Summary

The global vascular patches market size was valued at USD 505.1 million in 2025 and is projected to grow from USD 534.1 million in 2026 to USD 842.7 million by 2033, at a CAGR of 6.7% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 36.1% in 2025. The rising prevalence of peripheral artery disease, carotid artery disease, diabetes, and other atherosclerotic conditions, particularly among older adults, is increasing the need for vascular interventions. The use of vascular patches in endarterectomy, peripheral vascular reconstruction, arterial repair, and arteriovenous access revisions further supports market demand.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The increasing prevalence of peripheral artery disease (PAD), carotid artery disease, and atherosclerosis is creating a larger patient pool requiring vascular interventions. PAD causes narrowing or blockage of peripheral arteries and can progress to severe limb complications, increasing the need for revascularization and arterial repair. This growing disease burden is expected to support demand for vascular patches used in arterial reconstruction and repair. According to the American Limb Preservation Society (ALPS), the study published in Research projects a 220% increase in global peripheral artery disease (PAD) cases, rising from 113 million in 2021 to more than 360 million by 2050.

To learn more about this report, Download Free Sample Report

“What we found is both alarming and actionable,” said Dr. Wuquan Deng, senior author of the study and professor at Chongqing University Central Hospital and King’s College London.  “If current trends continue, we are facing a doubling of PAD mortality and a staggering 68% rise in disability burden. Yet, by prioritizing aggressive management of diabetes, obesity, and hypertension, we could prevent over 30% of this burden.”

“This is a call to action,” said Dr. David G. Armstrong, co-author and Distinguished Professor of Surgery and Neurological Surgery with the Keck School of Medicine of USC. “PAD is the tip of a much larger metabolic iceberg. If we act decisively, we can not only prevent disease but reduce amputations and deaths. This study gives us a roadmap-and a responsibility-to do so.” He is also a podiatric surgeon with Keck Medicine of USC.

To learn more about this report, Download Free Sample Report

The continued use of peripheral vascular reconstruction, endarterectomy, arterial repair, and patch angioplasty is driving demand for vascular patches. FDA documentation confirms that vascular repair patches are used in the reconstruction of the carotid, renal, iliac, femoral, profunda, and tibial vessels, as well as arteriovenous access revisions. The broad range of surgical applications provides a stable clinical basis for the adoption of vascular patches.

Furthermore, advancements in biologic vascular patches, particularly bovine pericardial and decellularized tissue materials, are improving biocompatibility, handling, durability, and tissue integration. Products such as VASCU-GUARD and XenoSure demonstrate the established use of biologic patches for vascular reconstruction and repair, including peripheral vascular procedures. Continued development of biologic materials is expected to strengthen their adoption across vascular surgery.

For instance, in July 2026, Medical Xpress reported a technological advancement in vascular patch development involving vascular organoid patches for treating ischemic heart disease. Researchers at Stanford University developed vascular organoids from human cells and surgically implanted them onto the surface of the hearts of pigs with ischemic heart disease. The patches survived for several weeks, promoted the formation of new microvessels, increased vessel density and maturity, and improved blood flow and cardiac function. The technology combines endothelial progenitor cells with mesenchymal stem cell-derived smooth muscle cells, offering a regenerative approach that could expand vascular patch applications beyond conventional structural repair toward biological tissue regeneration.

Market Dynamics

The market for vascular patches is shaped by the rising burden of vascular disease, continued use of endarterectomy and arterial reconstruction, and increasing adoption of biologic and advanced patch materials. Competition between biologic and synthetic patches remains strong, while newer materials such as extracellular-matrix patches are creating opportunities for product differentiation through improved tissue integration and remodeling. However, endovascular alternatives, material-related complications, clinical evidence requirements, and regulatory considerations influence the pace of adoption across different applications.

Market Concentration & Characteristics

The market demonstrates a moderate-to-high degree of innovation, driven by the development of decellularized biologic materials, advanced biomaterials, and tissue-engineered scaffolds designed to improve biocompatibility and vessel integration. Research into electrospun and bioactive scaffolds is further enabling control over mechanical properties, cellular response, and tissue regeneration.

The market has a moderate level of mergers and acquisitions, with established medical-device companies selectively pursuing acquisitions to broaden their vascular product portfolios and add complementary technologies. M&A activity is primarily focused on biologic vascular repair technologies, cardiovascular biomaterials, and peripheral vascular surgical products. Overall, companies are using acquisitions as a targeted strategy to strengthen product capabilities and expand their presence across vascular surgery.

To learn more about this report, Download Free Sample Report

Regulatory requirements have a moderate impact on the market as products must meet safety, performance, manufacturing, labeling, and post-market surveillance requirements before commercialization. In the U.S., vascular patch devices such as those under FDA product code DXZ are classified as Class II devices and generally follow the 510(k) pathway, creating compliance requirements while providing a defined route to market.

The market has a high concentration of end-use in vascular surgery and cardiovascular procedures, particularly carotid endarterectomy, peripheral vascular reconstruction, arterial repair, and suture-line reinforcement. FDA-cleared products indicate applications across carotid, renal, iliac, femoral, profunda, and tibial vessels, as well as arteriovenous access revisions. Therefore, demand is concentrated in hospitals, vascular surgery centers, and cardiovascular surgical settings, where these procedures are routinely performed.

Analyst Perspective

The market for vascular patches is expected to remain clinically established and competitive, supported by continued use in carotid endarterectomy, peripheral arterial reconstruction, vascular trauma, and AV-access repair. Competition is likely to center on biologic, synthetic, and biosynthetic materials, with differentiation driven by biocompatibility, durability, resistance to infection, handling characteristics, and tissue integration. Innovation in regenerative and tissue-engineered patch materials is also creating opportunities for next-generation products, particularly those designed to promote remodeling and reduce complications. Established products are expected to retain a strong clinical position while newer materials gradually expand their share through improved performance and clinical evidence.

Material Insights

The biologic segment dominated the market in 2025, driven by the widespread use of biologic materials, such as bovine pericardium and decellularized tissue, for vascular reconstruction and repair. LeMaitre Vascular reported that its biologic offerings, including XenoSure, CardioCel, and VascuCel patches, accounted for 53% of its total sales in 2025, underscoring the strong commercial presence of biologics.

The clinical use of bovine pericardial patches in procedures such as common femoral endarterectomy, along with ongoing regulatory scrutiny of biologically derived vascular patches, further supports the segment’s strong position.

The biosynthetic segment is expected to grow at the fastest CAGR during the forecast period, driven by increasing adoption of advanced vascular patch materials for arterial repair and patch angioplasty. Continued clinical evaluation of biologically derived and biosynthetic patches, including bovine pericardial patches used in femoral thromboendarterectomy, is supporting surgeons' acceptance of these patches and encouraging innovation in vascular patch design.

Application Insights

The hemodialysis/AV access surgery segment dominated the market in 2025 and is expected to grow at the fastest CAGR over the forecast period, supported by the recurring need to maintain and reconstruct arteriovenous fistulas and grafts in patients receiving hemodialysis. For instance, in February 2026, NCBI published a study evaluating PTFE patch angioplasty in 14 patients with hemodialysis-access dysfunction. The study reported 100% technical success, with primary patency rates of 92.3% at 3 months, 81.8% at 6 months, and 77.8% at 12 months, demonstrating the continued clinical use of vascular patches in dialysis-access reconstruction.

The peripheral artery reconstruction segment is expected to grow significantly over the forecast period, driven by increasing demand for surgical treatment of peripheral arterial disease and complex arterial occlusions. Vascular patches are used in procedures such as femoral endarterectomy and patch angioplasty to enlarge and reinforce the artery after plaque removal. Growing adoption of biologic patches and continued clinical use in peripheral arterial reconstruction are expected to create sustained demand for vascular patches.

Surgery Insights

The open surgery segment dominated the market in 2025, as vascular patches are widely used during open procedures such as carotid endarterectomy, femoral endarterectomy, and arterial reconstruction. For instance, in January 2025, a ScienceDirect-published multicenter study in Annals of Vascular Surgery evaluated common femoral thromboendarterectomy with patch angioplasty using vein and bovine pericardial patches. The study reported 2-year primary patency rates of 95.6% for vein patches and 92.8% for bovine pericardial patches, supporting the continued clinical use of vascular patches in open vascular surgery.

The hybrid surgery segment is expected to grow at the fastest CAGR during the forecast period, driven by increasing use of combined open and endovascular techniques for complex vascular disease. For instance, in February 2026, an NCBI-indexed study evaluated hybrid revascularization combining common femoral endarterectomy with bovine pericardial patch angioplasty and endovascular iliac recanalization in 28 patients, achieving an 85.7% technical success rate, supporting the growing use of vascular patches in hybrid procedures.

End-use Insights

The hospital segment dominated the market in 2025, as hospitals perform most complex vascular procedures requiring patch angioplasty, including carotid endarterectomy, peripheral vascular reconstruction, and arterial repair. The availability of specialized vascular surgeons, advanced operating facilities, intensive care units, and comprehensive postoperative monitoring further supports hospitals as the primary end users of vascular patches.

To learn more about this report, Download Free Sample Report

The ambulatory surgical centers (ASCs) segment is expected to grow at the fastest CAGR during the forecast period, supported by the shift of selected vascular procedures toward outpatient settings, driven by lower costs, shorter stays, and advances in minimally invasive techniques. For instance, in November 2025, an NCBI-indexed study found that ASC/office-based settings accounted for 46.72% of lower-extremity revascularizations by 2023, indicating a rapid shift of vascular care toward ambulatory settings. While vascular patches are primarily used in open procedures, increasing adoption of outpatient vascular surgery is expected to create opportunities for patch-based repairs in appropriately selected patients.

Regional Insights

The North America vascular patches industry dominated the global market with a revenue share of 36.1% in 2025. The North America market is supported by the region’s high prevalence of vascular diseases, advanced surgical infrastructure, and the availability of specialized vascular care services. The U.S. and Canada have established capabilities for carotid endarterectomy, peripheral vascular reconstruction, arterial repair, and dialysis-access procedures, creating consistent demand for vascular patches. The presence of established medical-device manufacturers and the continued development of biologic and synthetic patch materials further support market growth.

To learn more about this report, Download Free Sample Report

U.S. Vascular Patches Market Trends

The U.S. vascular patches industry is supported by the substantial burden of vascular disease and the established use of patch angioplasty in vascular surgery. The CDC estimates that approximately 6.5 million U.S. adults aged 40 years and older have peripheral artery disease, creating a significant patient pool for vascular interventions.  In addition, a U.S. study of 1,481 carotid endarterectomies found that 67.5% used bovine pericardial patches, demonstrating strong clinical adoption of vascular patches.

Europe Vascular Patches Market Trends

The Europe vascular patches industry is supported by a well-established vascular healthcare system, a substantial burden of cardiovascular and peripheral vascular diseases, and continued use of surgical vascular repair procedures. The European Society for Vascular Surgery recommends routine patch closure following conventional carotid endarterectomy, reflecting the established clinical role of vascular patches in the region. The availability of advanced biologic and synthetic patch materials and specialized vascular-surgery centers further supports market demand.

The vascular patches industry in the UK is supported by an established vascular care system, continued demand for carotid and peripheral vascular procedures, and the routine use of patch angioplasty in selected surgeries. The UK National Vascular Registry recorded 2,877 carotid endarterectomies in 2024, while NHS data reported 16,618 lower-limb revascularisation procedures during the year. The continued use of vascular patches in carotid endarterectomy and peripheral vascular repair supports sustained demand across the UK.

The France vascular patches industry is supported by a significant burden of peripheral and arterial diseases, with 68,702 adults hospitalized for lower-extremity arterial disease in 2022 and more than 760,000 adults affected by the condition.  The continued use of patch angioplasty in carotid endarterectomy and peripheral vascular reconstruction, supported by France’s established vascular-care infrastructure, is expected to sustain demand for vascular patches.

Asia Pacific Vascular Patches Market Trends

The Asia Pacific vascular patches industry is supported by the region’s large patient population, increasing prevalence of cardiovascular and peripheral vascular diseases, and improving access to vascular surgical care. Rising healthcare expenditure, expansion of hospitals and specialized vascular centers, and increasing adoption of advanced biologic and synthetic vascular patches are contributing to market development. Growing awareness of vascular disease and improvements in surgical capabilities are expected to further support demand for vascular patches across the region.

The vascular patches industry in Japan is supported by an established vascular-surgery system, a large aging population, and continued demand for arterial reconstruction and endarterectomy procedures. Japan’s vascular-surgery database records substantial volumes of open arterial procedures and vascular access operations, providing a clinical basis for vascular patch use. Although patch angioplasty remains less widely adopted in Japan than in some Western markets, clinical evidence supports its use in carotid endarterectomy, particularly to reduce the risk of restenosis.

Latin America Vascular Patches Market Trends

The Latin America vascular patches industry is supported by the growing burden of peripheral vascular disease and increasing demand for vascular interventions. A multicenter Latin American registry reported a high prevalence of critical limb-threatening ischemia, diabetes, hypertension, and dyslipidemia among patients undergoing peripheral interventions, indicating a substantial need for vascular repair. Improving vascular surgery capabilities and healthcare infrastructure in countries such as Brazil and Argentina is expected to support the adoption of vascular patches.

Middle East & Africa Vascular Patches Market Trends

The MEA vascular patches industry is supported by the growing burden of peripheral arterial disease, diabetes, and other vascular conditions across the region. North Africa and the Middle East recorded approximately 6.14 million PAD cases among older adults in 2021, highlighting a substantial patient population requiring vascular interventions. Improving vascular care infrastructure and increasing access to surgical treatment are expected to support the adoption of vascular patches for arterial repair, reconstruction, and endarterectomy.

Key Vascular Patches Company Insights

The vascular patches industry is competitive and moderately fragmented, with major participants including LeMaitre Vascular, W. L. Gore & Associates, B. Braun, Getinge, and Baxter. Market share is distributed among several manufacturers, with competition based on biologic and synthetic patch portfolios, product performance, clinical adoption, regulatory approvals, and geographic presence, rather than being controlled by a single dominant company.

Key Vascular Patches Companies:

The following key companies have been profiled for this study on the vascular patches market:

• Vygon

• Baxter International Inc.

• LeMaitre Vascular, Inc.

• W. L. Gore & Associates, Inc.

• Getinge AB

• B. Braun Melsungen AG

• Artivion, Inc.

• Edwards Lifesciences Corporation

• Elutia Inc. (formerly Aziyo Biologics)

• Becton, Dickinson and Company (BD)

• Labcor Laboratórios Ltda.

• VUP Medical a.s.

• Aegis Lifesciences Pvt. Ltd.

Recent Developments

• In May 2026, Artivion, Inc. completed the acquisition of Endospan Ltd., a long-standing partner and developer of the NEXUS Aortic Arch System, strengthening Artivion’s portfolio in endovascular treatment of aortic arch disease. Artivion funded the transaction with its previously drawn USD 150 million delayed-draw term loan, including a USD 135 million upfront net purchase price, with additional consideration contingent on commercial performance.

• In June 2025, Aortyx secured USD 16.0 million in Series A funding led by Ship2B Ventures and Clave Capital. The funding was intended to accelerate the development of Aortyx’s next-generation aortic patch technology and support first-in-human clinical trials within two years. Following successful animal and cadaver studies, the company planned to advance through clinical and regulatory pathways while expanding its patch platform for aneurysms and other aortic conditions in the EU and U.S. markets.

Global Vascular Patches Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vascular patches market report based on material, application, surgery, end-use, and region:

• Material Outlook (Revenue, USD Million, 2021 - 2033)

  • Biologic

  • Synthetic

  • Biosynthetic

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Carotid Endarterectomy

  • Peripheral Artery Reconstruction

  • Aortic & Cardiac / Congenital Repair

  • Hemodialysis / AV Access Surgery

  • Trauma & Other Vascular Repairs

• Surgery Outlook (Revenue, USD Million, 2021 - 2033)

  • Open Surgery

  • Hybrid Surgery

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Specialty Cardiac & Vascular Centers

  • Ambulatory Surgical Centers

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Sweden

    • Denmark

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The vascular patches market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each vascular patches segment quantified using the revenue-capture definitions in the table below.

Estimation Model

To learn more about this report, Download Free Sample Report

Delivered Customizations

This report has been delivered with the following In-depth customizations